An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the tolerability, the initial safety profile, as evaluated by an analysis of laboratory results and adverse event (AE) reporting.
2 years
Yes
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
3129K2-1105
NCT01055496
March 2010
February 2015
Name | Location |
---|---|
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Federal Way, Washington 98003 |
Pfizer Investigational Site | Clearwater, Florida 33761 |
Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |
Pfizer Investigational Site | Livingston, New Jersey 07039 |